{"id":"W2739450515","doi":"10.1177/1753465817717134","title":"Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Respiratory Disease","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Teva Pharmaceutical Industries; Merck","keywords":"Benralizumab; Medicine; Mepolizumab; Asthma; Eosinophil; Endotype; Immunology; Tolerability; Eosinophilia; Placebo; Internal medicine; Adverse effect; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002679777,0.0004871183,0.002478969,0.0003117034,0.0002147284,0.001010729,0.0006500506,0.001556011,0.003741981],"category_scores_gemma":[0.00202664,0.0001787938,0.001900422,0.0004841441,0.0004426105,0.0009059975,0.0002491052,0.002755579,0.0005819835],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005259304,"about_ca_system_score_gemma":0.0006358085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007439574,"about_ca_topic_score_gemma":0.002650628,"domain_scores_codex":[0.999414,0.000308792,0.00006777842,0.00004951478,0.00009400817,0.00006600715],"domain_scores_gemma":[0.9989045,0.0004571091,0.0002633048,0.00003710613,0.0001353053,0.0002028108],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.1953798,0.006358444,0.004344588,0.02496007,0.007579567,0.0004259514,0.0002691519,0.001355685,0.008087513,0.002404023,0.02716961,0.7216656],"study_design_scores_gemma":[0.526455,0.1700915,0.04195107,0.01974279,0.01516823,0.001426897,0.0004770181,0.003131563,0.00370684,0.004144699,0.2135205,0.0001839035],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1083954,0.8732508,0.0006296916,0.007634846,0.001604463,0.001002803,0.0007966966,0.0001025344,0.006582725],"genre_scores_gemma":[0.4354039,0.5314728,0.003420637,0.01772337,0.002950031,0.002181055,0.001967314,0.00005095637,0.004829939],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003741981,"threshold_uncertainty_score":0.0141722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1004534049370695,"score_gpt":0.427334420223989,"score_spread":0.3268810152869196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}